Date:4/25/2012

nd intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
2. Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
3. Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
4. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Lexicon Announces Commencement of Rights Offering to Stockholders
6. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
8. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
9. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
10. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
11. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference